Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.93 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.93 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.93 |
| ▸ | PGR | P06401 | 3/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.93 |
| ▸ | SHBG | P04278 | 2/20 | 0.93 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.93 |
| ▸ | MAPT | P10636 | 2/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | AR | P10275 | 2/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL29081596 | 0.99 | HIF1A (0.91) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL2433004 | 0.97 | HIF1A (0.91) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL10292969 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL10261067 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL6932400 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL24900238 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL13202859 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL5699764 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL15114813 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL13046615 | 0.96 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019871-A2 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2016-05-18 | — | — | EP | claimed |
| WO-2015006657-A2 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER | THE UNITETD STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-01-15 | — | — | WO | claimed |
| US-4082613-A | PSEUDOSACCHAROMYCETE | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1978-04-04 | — | — | US | claimed |
| US-20260139001-A1 | EVOLUTION OF FLUOROGENIC SENSORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4594333-A2 | EVOLUTION OF FLUOROGENIC SENSORS | President and Fellows of Harvard College (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025068686-A1 | TREATMENT FOR BATTEN DISEASE | THE ROYAL VETERINARY COLLEGE (GB) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024073568-A2 | EVOLUTION OF FLUOROGENIC SENSORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-115996703-A | Compositions and methods for treating ocular disorders by contact lens mediated drug delivery | 奇奥拉制药股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4125813-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE BY CONTACT LENS MEDIATED DRUG DELIVERY | Kiora Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11555818-B2 | Method for the diagnosis and prognosis of cancer | The USA, as represted by the Secretary, Dept. of and Human Services, National Institutes of Health (US) | 2023-01-17 | — | — | US | disclosed |
| US-20210299039-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE BY CONTACT LENS MEDIATED DRUG DELIVERY | EYEGATE PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2015006657-A2 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER | THE UNITETD STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015006657-A2 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER | THE UNITETD STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-01-15 | — | — | WO | disclosed |
| US-8791093-B2 | Pharmaceutical delivery systems for treatment of substance abuse and other addictions | GOOBERMAN LANCE L (US) | 2014-07-29 | — | — | US | disclosed |
| US-20120164207-A1 | Degradable networks for sustained release and controlled release depot drug delivery applications | GOOBERMAN LANCE L (US) | 2012-06-28 | — | — | US | disclosed |
| US-20100311704-A1 | PHARMACEUTICAL DELIVERY SYSTEMS FOR TREATMENT OF SUBSTANCE ABUSE AND OTHER ADDICTIONS | GOOBERMAN LANCE L | 2010-12-09 | — | — | US | disclosed |
| US-20100196436-A1 | IMPLANTS CONTAINING DISULFIRAM AND AN ANTI-INFLAMMATORY AGENT | GOOBERMAN LANCE L | 2010-08-05 | — | — | US | disclosed |
| CN-1740175-A | Plumepoppy total alkaloid salt and its prepn and application | CHANGSHA SHIWEI SCI TECH CO LT (CN) | 2006-03-01 | — | — | CN | disclosed |
| US-6203813-B1 | OPIATE ANTAGONIST, STEROIDAL ANTIINFLAMMATORY AGENT AND CARRIER; SUSTAINED RELEASE; DRUG ABUSE TREATMENT | GOOBERMAN, LANCE L. | 2001-03-20 | — | — | US | disclosed |
| US-4082613-A | PSEUDOSACCHAROMYCETE | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139001-A1 | EVOLUTION OF FLUOROGENIC SENSORS | EIF2A, SARS1, EIF2B1 | NR3C1 1541/4885HIF1A 3853/4885HSD17B10 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.